ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2022-03-29
Target enrollment:
Participant gender:
Summary
This study evaluates the anti-tumor effects of ORIN 1001 in patients with advanced solid
tumors or relapsed refractory metastatic breast cancer (patients with progressive disease
after receiving at least two lines of therapy in the advanced setting).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Orinove, Inc. Shanghai Fosun Pharmaceutical Development Co, Ltd.